Cash flows from operating activities: | |
Net loss | -193.1M |
Adjustments to reconcile net loss to net cash provided by (used in) operating activities: | |
Depreciation and amortization | 8.61M |
Deferred income taxes | |
Non-cash income tax benefit | |
Non-cash stock-based compensation | 39.3M |
Charge for 401(k) company stock match | |
Equity in loss of joint venture (Regulus Therapeutics Inc.) | |
Changes in operating assets and liabilities: | |
Collaboration receivables | -1.22M |
Income taxes receivable | |
Prepaid expenses and other assets | -5.59M |
Accounts payable | -3.59M |
Income taxes payable | |
Accrued expenses and other | 1.72M |
Deferred revenue | 5.38M |
Net cash used in operating activities | |
Cash flows from investing activities: | |
Purchases of property and equipment | -24.38M |
Purchases of marketable securities | |
Sales and maturities of marketable securities | 605.98M |
Net cash provided by (used in) investing activities | |
Cash flows from financing activities: | |
Proceeds from issuance of common stock | 6.27M |
Proceeds from issuance of shares to Novartis | 0 |
Net cash provided by financing activities | |
Effect of exchange rate on cash | |
Net decrease in cash and cash equivalents | 90.18M |
Cash and cash equivalents, beginning of period | 180.9M |
Cash and cash equivalents, end of period | 271.08M |